9-alpha estratriene derivatives as ERbeta selective ligands for the prevention and treatment of intestinal cancer

Details for Australian Patent Application No. 2009268302 (hide)

Owner Bayer Schering Pharma Aktiengesellschaft

Inventors Hertrampf, Torsten; Diel, Patrick; Fritzemeier, Karl-Heinrich

Agent Davies Collison Cave

Pub. Number AU-A-2009268302

PCT Pub. Number WO2010/003700

Priority 61/080,333 14.07.08 US; 08160239.3 11.07.08 EP

Filing date 9 July 2009

Wipo publication date 14 January 2010

International Classifications

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/567 (2006.01) - substituted in position 17 alpha, e.g. mestranol, norethandrolone

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

27 January 2011 PCT application entered the National Phase

  PCT publication WO2010/003700 Priority application(s): WO2010/003700

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009268303-Wheat starch and wheat flours and foodstuffs containing these wheat starch/wheat flours

2009268290-Compositions and methods of making compositions